Full history for every metric is available with a Kvantra account
Sequana Medical N.V. (SEQUA.BR)
Key financial summary
Financials in EUR| 2019 | 2020 | 2021 | 2022 | 2023 | 2024 | ||
|---|---|---|---|---|---|---|---|
| Total revenue | €m | 1 | 1 | 0 | 1 | 1 | 0 |
| Operating profit | €m | -19 | |||||
| Net profit | €m | -15 | -19 | -24 | -31 | -33 | -45 |
| EPS reported | € | -1.22 | |||||
| Operating cashflow per share | € | -0.56 | |||||
| Capex per share | € | 0.00 | |||||
| FCF per share | € | -0.56 | |||||
| Free cash flow | €m | -21 | |||||
| Net debt | €m | 36 | |||||
| Book value equity | €m | -44 | |||||
| Book value per share | € | -1.21 | |||||
| Number of shares | m | 36.6 | |||||
| DPS (TTM paid) | € | 0.00 |
Financial summary
Financials in EUR| 2019 | 2020 | 2021 | 2022 | 2023 | 2024 | ||
|---|---|---|---|---|---|---|---|
| Value | |||||||
| P/E TTM | x | - | |||||
| P/B LTM | x | -2.52 | |||||
| P/S LTM | x | 1,056.61 | |||||
| P/FCF LTM | x | -5.46 | |||||
| EV/EBITDA LTM | x | -8.53 | |||||
| EV/Sales LTM | x | 1,399.10 | |||||
| Earnings Yield LTM | % | -39.87% | |||||
| FCF Yield | % | -18.32% | |||||
| Quality | |||||||
| ROE | % | 100.62% | |||||
| ROIC | % | 540.85% | |||||
| Operating margin | % | -17647.2% | |||||
| Gross margin | % | -2092.5% | |||||
| FCF/Sales | % | -19353.8% | |||||
| Growth and momentum | |||||||
| EPS Growth YoY | % | - | |||||
| Sales Growth YoY | % | -85.12% | |||||
| Net Income Growth YoY | % | - | |||||
| FCF Growth | % | - | |||||
| Operating Profit Growth | % | - | |||||
| Dividend and capital structure | |||||||
| Dividend Yield | % | 0.00% | |||||
| Dividend Growth | % | 0.00% | |||||
| Payout Ratio | % | 0.00% | |||||
| FCF/Debt | x | -0.51 | |||||
| Net Debt/EBITDA | x | -2.09 | |||||
| EBIT/Net interest | x | -0.71 | |||||
| Net debt/market cap | % | 32.04% | |||||
| Net debt/Equity | x | -0.81 | |||||
| Gross debt/equity | x | -0.90 | |||||
Company overview
Sequana Medical N.V. is a medical technology company that has reached the commercial stage, dedicated to creating innovative solutions for managing excessive fluid accumulation linked to liver conditions, malignant ascites, and heart failure. The company's key offerings include the alfapump® system, an implanted device specifically designed to treat severe and resistant liver ascites as well as malignant ascites (fluid buildup caused by cancer). Additionally, it provides Direct Sodium Removal (DSR) technology to address ongoing fluid congestion in patients with heart failure. This DSR technology is integrated into the alfapump® DSR system, a fully implantable solution for direct sodium removal therapy in heart failure patients experiencing fluid overload. Established in 2006 and headquartered in Ghent, Belgium, Sequana Medical operates across Belgium, Germany, France, Switzerland, and other international regions.
Similar companies
For informational purposes only. Kvantra provides data and quantitative analysis, not investment advice. KvantraRank is a mechanical model output. Analyst price targets and ratings are sourced from third parties and are not Kvantra recommendations. Past performance does not guarantee future results; all investments carry risk.
Sequana Medical N.V. (SEQUA.BR)
Sequana Medical N.V. is a medical technology company that has reached the commercial stage, dedicated to creating innovative solutions for managing excessive fluid accumulation linked to liver conditions, malignant ascites, and heart failure. The company's key offerings include the alfapump® system, an implanted device specifically designed to treat severe and resistant liver ascites as well as malignant ascites (fluid buildup caused by cancer). Additionally, it provides Direct Sodium Removal (DSR) technology to address ongoing fluid congestion in patients with heart failure. This DSR technology is integrated into the alfapump® DSR system, a fully implantable solution for direct sodium removal therapy in heart failure patients experiencing fluid overload. Established in 2006 and headquartered in Ghent, Belgium, Sequana Medical operates across Belgium, Germany, France, Switzerland, and other international regions.
Unlock all fundamental data
Sign up for FreeUnlock all fundamental data
Sign up for Free